WSJ : Pimco ETF Draws Probe by SEC

Pimco ETF Draws Probe by SEC
Regulators Are Probing Whether Returns Were Artificially Inflated for an ETF at Bill Gross's Firm

The Securities and Exchange Commission is investigating whether bond giant Pacific Investment Management Co. artificially boosted the returns of a popular fund aimed at small investors, according to people familiar with the matter, the latest challenge for the firm run by investor Bill Gross.

A probe into pricing issues at Pimco has been under way for some months, the people familiar with the matter said. Mr. Gross has been interviewed by SEC investigators, the people said. Mr. Gross declined to comment for this article.

The issues being scrutinized by the SEC include the way a flagship exchange-traded fund, managed by Mr. Gross, purchased and valued certain bonds. Investigators from the SEC's enforcement division are examining whether the $3.6 billion Pimco Total Return ETF BOND +0.08% bought investments at discounted prices but relied on higher valuations for the investments when the fund calculated the value of its holdings shortly thereafter. Such a maneuver could make it seem as though the ETF had scored quick gains when it was in fact taking advantage of variations in the way some investments are valued in the bond market.

One possible focus of the SEC inquiry, according to people familiar with the matter: whether Pimco's alleged maneuver meant investors were given inaccurate information about the fund's performance. It is a breach of securities law to provide investors with misleading information about values or performance, even if the wrong information was supplied unintentionally.

Pimco "has been cooperating with the SEC in this nonpublic matter, and we take our regulatory obligations and responsibilities to our clients very seriously. We believe our pricing procedures are entirely appropriate and in keeping with industry best practices," said a spokesman for the firm.

A spokesman for the SEC declined to comment.

An ETF is a mutual fund that trades on an exchange like a stock, allowing investors to move in and out of it quickly.

The inquiry comes amid escalating scrutiny by the SEC of whether investment funds are valuing assets accurately and fairly, according to officials there. The agency has brought several recent improper-pricing civil cases against firms, fund managers and others. A number of these cases focused on conduct during the 2008 financial crisis, when cratering values for subprime-mortgage assets caused some funds to fail. Those cases settled without firms or individuals admitting or denying liability.

For Pimco, the probe comes as the Newport Beach, Calif., firm battles a wave of investor withdrawals from its $222 billion Total Return Fund, managed by Mr. Gross. The departing cash has come amid spotty performance at the fund and a management shake-up earlier this year, highlighted by the abrupt departure of Mr. Gross's onetime heir apparent, Mohamed El-Erian. Since May 2013, more than $65 billion has left the fund, which trails its benchmark this year. Investors also have been pulling money across all of Pimco's mutual funds.

Mr. Gross, 70 years old, is one of the most successful bond investors ever. He is considered the driving force behind Pimco's growth into a blue-chip money manager, with almost $2 trillion in assets under management as of June 30. Pimco is a unit of German insurer Allianz SE. ALV.XE -0.76%

It isn't clear any of the actions by Pimco that are being examined are improper. It can be difficult to ascertain proper valuations in the debt markets, especially for bonds that are relatively small in dollar terms or don't trade frequently.

The Pimco investigation has been under way for at least a year but appears to have intensified in recent weeks, according to people familiar with the matter. Regulators recently have been interviewing Pimco executives, according to some of these people. At least six months ago, Mr. Gross spent over a day being interviewed by SEC officials.

The investments believed to be in question, such as small amounts of mortgage securities—or "odd lots" in the terminology of the financial markets—tend to receive lower prices because of their small sizes or because they are backed by smaller institutions, among other factors.

After the launch of the ETF, Wall Street traders were encouraged by Pimco to offer these small securities to the Pimco ETF, according to some of the people familiar with the matter. Mortgage bonds with a relatively small $500,000 face amount, for example, might have sold for only $480,000, because few investors wanted them, due to the small size.

But when Pimco, shortly after purchasing the bonds, placed a value on them, it typically used outside pricing companies that often assigned higher valuations because they used a similar, but much larger, pool of mortgage bonds to compare them with, according to people close to the firm. Placing a $500,000 valuation on a bond purchased for $480,000, for example, would have allowed Pimco to claim a quick 4% gain on the $500,000 bond, or $20,000.

If that maneuver happened with enough bonds, early results of the ETF could have been aided, these people say.

Traders say buying discounted bonds, then using an outside ratings company to place a higher valuation on those bonds, is akin to buying a used car on the cheap because it is in poor shape but having a lender rely on the list price when making a loan.

It isn't clear how widespread this maneuver is in the bond market. It also isn't clear how much the alleged activity by Pimco might have helped the results of the ETF, if at all.

The fund scored huge early gains, potentially helping it attract interest from investors. The ETF was launched Feb. 29, 2012, with $103 million as a companion to Mr. Gross's much-larger Pimco Total Return fund and designed to follow a similar strategy.

The Pimco Total Return ETF returned 8.7% between March and August of 2012, its first six months in existence, compared with 5.2% for the Pimco Total Return fund and 2.9% for the Barclays BARC.LN -1.04% Capital U.S. Aggregate bond index, according to researcher Morningstar Inc. Since inception through August, the ETF has gained 5.9%, compared with a 3.4% gain for the Total Return fund and 2% for the Barclays index.

Amid the strong early performance, the fund gathered more than $2.4 billion in its first six months, an astonishing rate for a mutual fund or exchange-traded fund, according to analysts.

The heady performance of the ETF raised questions among some of Pimco's clients about the discrepancy in results between the ETF and the Total Return fund, according to a person close to the firm.

Many bonds don't trade frequently, making it a challenge to determine an accurate price. That is one reason mutual funds and others turn to outside pricing companies to set periodic valuations for their investments and funds. The pricing companies in some cases find it difficult to get a sense of the latest prices and valuations, especially for infrequently traded bonds or those in small sizes, and sometimes rely on valuation models, traders say. The models don't always do a good job taking size and other factors into consideration, however, which is why, in some cases, they place full valuations on unpopular bonds, like those the Pimco ETF is said to have purchased, traders say.

>>> Asia Update

Asian Market Update: New Zealand trade deficit smaller than feared, even as Fonterra cuts payout forecast again

***Economic Data*** - (NZ) NEW ZEALAND AUG TRADE BALANCE (NZ$): -472M (2nd consecutive trade deficit) V -1.1BE - (AU) AUSTRALIA AUG SKILLED VACANCIES M/M: 1.1% V 1.4% PRIOR (4th consecutive increase) - (AU) AUSTRALIA JUL CONFERENCE BOARD LEADING INDEX M/M: 0.5% (3rd consecutive increase) V 0.2% PRIOR - (JP) JAPAN SEPT PRELIM MARKIT/JMMA MANUFACTURING PMI: 51.7 V 52.2 PRIOR (4th consecutive month of expansion) - (VN) Vietnam Sept Consumer Price Index (CPI) Y/Y: 3.6% v 4.3% prior

***Index Snapshot (as of 02:30 GMT)*** - Nikkei225 -0.3%, S&P/ASX -0.7%, Kospi flat, Shanghai Composite +0.2%, Hang Seng +0.1%, Dec S&P500 +0.1% at 1,974

***Commodities/Fixed Income/Currencies*** - Dec gold flat at $1,222, Nov crude oil flat at $91.56/brl, Dec copper +0.3% at $3.03/lb - (US) API PETROLEUM INVENTORIES: CRUDE: -6.5M (largest draw since May 20th) v +0.5Me, GASOLINE: +0.09M v -0.5Me, DISTILLATE: +3.0M v +0.5Me - GLD: SPDR Gold Trust ETF daily holdings fall 1.2 tonnes to 773.5 tonnes; Lowest level since Dec 2008, 3rd consecutive decline - SLV: iShares Silver Trust ETF daily holdings rise to 10,663 tonnes from 10,589 tonnes prior (highest since Apr 2013) - update - (JP) BOJ offers to buy ¥300B in 1-3yr JGB, ¥200B in 3-5yr JGB, ¥400B in 5-10yr JGB - (AU) Australia MoF (AOFM) sells A$600M in 4.75% 2027 bonds; Avg yield: 3.7698%; Bid-to-cover: 3.93x - USD/BRL: (BR) Brazil Central Bank increasing currency intervention; To offer up to 15K swap contracts vs 6K prior - financial press - USD/CNY: (CN) PBoC sets yuan mid point at 6.1462 v 6.1470 prior setting (2nd consecutive firmer Yuan setting)

***Market Focal Points/Key Themes*** - New Zealand dodged expectations for a 1-year high trade deficit above NZ$1B. Terms of trade still marked their 2nd consecutive monthly shortfall, but the figure was nowhere as bad as feared, with exports reaching NZ$3.5B v NZ$3.2Be and imports missing at NZ$4.0B v NZ$4.5Be. The beat offered a welcome relief to the Kiwi dollar, which hit a 1-year low near $0.8040 after dairy co-op Fonterra cut its FY14/15 payout to NZ$5.30/kg from NZ$6.00/kg. Fonterra also reported FY14 Net NZ$179M v NZ$736M y/y on Rev NZ$22.3B v NZ$18.6B y/y, and raised its FY15 dividend forecast to NZ$0.25-0.35/shr from NZ$0.20-0.25 prior forecast. Recall Fonterra has also cut its payout forecast due to oversupply as recently as late July. Following the trade figures, NZD/USD reversed that post Fonterra-drop to as high as $0.8085.

- Japan PM Abe noted he would prefer some caution related to the impact of recent Yen weakness on local economies. Markets briefly interpreted that as an expression of discomfort related to the side-effects of weak-JPY policy pursued by the BOJ, sending USD/JPY down about 30pips below ¥108.50. Also of note in Japan, prelim Sept Markit PMI showed its 4th month of expansion, with output increasing at faster rate and Output Prices reversing direction to the upside.

- China markets remain supported by chatter of policymakers' easing of housing curbs. Early-session reports noted cities of Qingdao, Fuzhou, Suzhou, Hangzhou, and Nanjing had reportedly eased their criteria for "first mortgage" home purchase classification to buyers with no mortgage outstanding and with no house registered under their names. Wuhan was also listed as a city stimulating housing demand by fully removing home purchasing curbs effective Sept 24th. Separately, Goldman Sachs cut its China 2015 GDP forecast to 7.1% from 7.6% prior, forecasting policymakers would lower their 2015 target to 7.0% from 7.5% in 2014. CPI projections were also downgraded for 2014 and 2015 to 2.2% and 2.5% respectively.

- Australia Bureau of Resources (BREE) lowered its iron ore price projections to $94/ton for both 2014 and 2015 vs $105/ton and $97/ton respective forecasts made in June. BREE also noted export earnings growth would slow to an annual 7% from the 12% expected this year. BREE saw continued growth in volumes helping offset lower commodity prices, and also mentioned the positive impact of lower AUD. RBA released its semi-annual Financial Stability Review, hinting it would consider macro-prudential measures to curb growing property prices in the current low-rate environment. RBA said it was in talks with regulators over additional house lending clamps, warning lending is becoming unbalanced and could pose a risk to the financial system.

***Equities*** US markets: - BBBY: Reports Q2 $1.17 v $1.14e, R$2.95B v $2.90Be; Guides Q3 Rev +2.8-3.7% y/y v +4%e (implies R$2.95-2.98B v $2.98Be); SSS +2-3% - conf call; +7.8% afterhours - ZSPH: Announces positive top-line results from HARMONIZE (ZS004); +5.1% afterhours - VZ: Said to hire TAP Advisors for sale/lease of up to 12K towers; May raise $6B based on previous AT&T sale - financial press; flat afterhours - AIR: Reports Q1 $0.36 v $0.41e, R$469M v $496Me; Cuts FY14 guidance; -3.5% afterhours - ATOS: Provides Regulatory and Commercial Update on Its ForeCYTE Breast Aspirator and Its FullCYTE Breast Aspirator; -52.8% afterhours - ECTE: Trading halted; Suspends operations to conserve liquidity; -69.8% afterhours

Notable movers by sector: - Consumer Discretionary: Daiei 8263.JP +16.5%, Aeon 8267.JP -2.4% (press speculation on Aeon's restructuring); Starbucks Coffee Japan 2712.JP +4.5% (Starbucks to purchase remaining stake) - Financials: China Vanke 2202.HK +1.6% (shareholder raises stake) - Materials: Nuplex Industries NPX.NZ +6.0% (confirms plan to sell assets) - Industrials: Amada 6113.JP +3.4% (press speculation on H1 results); Obayashi Corp 1802.JP +2.1% (project plans)

>>> US After Hours

After Hours Summary: BBBY +7.5%, GTI -12.6%, AIR -3.5% following earnings/guidance

After Hours Gainers: Companies trading higher in after hours in reaction to earnings: BBBY +7.5%

Companies trading higher in after hours in reaction to news: LPCN +15.9% (co to host a conference call and webcast tomorrow, September 24, 2014 at 8:45 a.m. Eastern time to discuss top-line results from its Study of Oral Androgen Replacement pivotal Phase 3 clinical study), ZSPH +5.1% (announced positive top-line results from HARMONIZE (ZS004), a second Phase 3 clinical trial of ZS-9 in patients with Hyperkalemia), LEI +0.5% (Condagua, LLC disclosed ~13% active stake in 13D filing; urges exploration of strategic alternatives)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings: GTI -12.6%, AIR -3.5%

Companies trading lower in after hours in reaction to news: ATOS -54.5% (announced that the FDA has issued a determination that the ForeCYTE Breast Aspirator is "not substantially equivalent" to its predicate device; not cleared for marketing in U.S.), MMLP -4.6% (commenced public offering of 3 mln common units under its existing shelf registration statement), GLOP -3.6% (announced public offering of 4.5 mln common units), SCTY -2.3% (announced launch of a $500 mln convertible senior notes offering), EVHC -2.2% (announced sale of 17,500,000 shares of stock by selling stockholders), LAND -2.0% (announced common stock offering of 1.15 mln shares), ALCS -2.0% (MFP Partners liquidated stake in the company)

>>> US Close Dow-0,68% S&P-0,58% Nasdaq -0,29%

Closing Market Summary: S&P 500 Logs Third Consecutive Loss

The stock market finished the Tuesday session on the defensive after spending the entire day in a steady retreat. The S&P 500 (-0.6%) posted its third consecutive decline, while the small-cap Russell 2000 (-0.9%) slipped behind the broader market during afternoon action.

Equity indices were pressured from the start following some overnight developments that weighed on sentiment. The market tried to overcome the early weakness, but could not stage a sustained rebound, which resulted in follow-through selling in the afternoon.

Mixed PMI data from the eurozone combined with an announcement from the U.S. Treasury concerning tax inversion deals factored into the cautious action. Under a new notice released by the Treasury Department, an inverted company is subject to potential adverse tax consequences if, after the transaction: (1) less than 25% of the new multinational entity's business activity is in the home country of the new foreign parent, and (2) the shareholders of the old US parent end up owning at least 60% of the shares of the new foreign parent. The same tax treatment would still apply if 80% or more of the new foreign parent is owned by the US parent company's shareholders.

Fittingly, the news caused early weakness in the health care sector (-0.6%), which has been at the center of recent M&A deals. The sector was able to cut its early loss in half, while Dow component Pfizer (PFE 30.05, -0.13) narrowed its loss to 0.4% by the close. The stock received an afternoon boost after Bloomberg reported the company has approached Actavis (ACT 240.87, +5.25) about a potential acquisition.

Elsewhere among influential sectors, financials (-0.7%) and technology (-0.2%) displayed relative strength at the start, but only the tech sector was able to end near its flat line. The top-weighted component, Apple (AAPL 102.64, +1.58), did some heavy lifting, while other influential names like Facebook (FB 78.29, +1.49) and Google (GOOGL 591.18, -6.09) ended mixed.

Outside of technology, the energy sector (-0.3%) was the only other cyclical outperformer, while crude oil rose 0.7% to $91.55/bbl. The other commodity-related sector—materials (-0.6%)—ended in line with the market.

Also of note, the industrial sector (-0.8%) struggled amid weakness in defense and transport stocks. The PHLX Defense Index lost 1.2% and the Dow Jones Transportation Average fell 0.8%.

The daylong retreat contributed to increased demand for volatility protection that sent the CBOE Volatility Index (VIX 14.87, +1.18) to its highest level in five weeks.

Treasuries ended on their highs with the 10-yr yield down four basis points at 2.53%.

Today's participation was ahead of recent averages with roughly 700 million shares changing hands at the NYSE floor.

Economic data was limited to the July Housing Price Index from the FHFA, which rose 0.1% to follow a revised increase of 0.3% (from 0.4%) observed during the prior month.

Tomorrow, the weekly MBA Mortgage Index will be released at 7:00 ET, while New Home Sales for August (consensus 435K) will cross the wires at 10:00 ET.

* Nasdaq Composite +8.0% YTD  * S&P 500 +7.3% YTD  * Dow Jones Industrial Average +2.9% YTD  * Russell 2000 -3.8% YTD

WSJ : Pfizer Held Takeover Talks With Actavis

Pfizer Held Takeover Talks With Actavis Talks Ended Last Week After Actavis Decided Against a Deal

Pfizer's talks with Actavis marked the drug company's second attempt this year to pursue an acquisition that would have lowered its U.S. taxes Timothy A. Clary/Agence France-Presse/Getty Images Pfizer Inc. PFE -0.43% explored a potential tax-lowering takeover of rival Actavis PLC in recent weeks, but talks between the two pharmaceutical companies have ended, according to a person familiar with the matter.

New York-based Pfizer approached Actavis proposing a cash-and-stock tie-up, according to the person. The talks ended last week after Actavis decided against a deal, the person said. It is unclear why. Actavis has a market value of about $60 billion.

News of the talks is the latest twist in a dramatic period for takeovers in the health-care industry, many of them driven by tax considerations. The Actavis talks marked the second attempt this year by Pfizer to pursue an acquisition that would have lowered its U.S. taxes: Earlier this year, Pfizer made an unsuccessful $120 billion offer for British rival AstraZeneca AZN.LN -3.57% PLC.

Actavis last year did its own tax-lowering deal, known as an inversion, by buying Warner Chilcott PLC for $5 billion. It then bulked up further this year by taking over Forest Laboratories Inc. in a $25 billion deal.

By buying Actavis, Pfizer could have assumed the company's Irish domicile and in the process become more tax-efficient.

Pfizer would have used its cash held overseas to help pay for the deal, the person said. The talks between Pfizer and Actavis fell apart amid resistance to inversions in Washington, but before the Treasury Department on Monday announced rules to deter them, which could discourage either side from resuming discussions.

At the time of the Pfizer discussions, Actavis was pursuing a takeover of Allergan Inc., AGN +1.84% an approach that was also rebuffed, The Wall Street Journal reported Monday.

Botox maker Allergan, trying to fight off a $53 billion hostile offer from Valeant Pharmaceuticals International Inc., VRX.T -0.02% is closing in on a takeover of Salix Pharmaceuticals Ltd. SLXP +5.84% , a deal that would make it more difficult and complicated for Valeant to succeed in the effort.

Others companies in the industry, including AbbVie Inc. ABBV -1.96% and Mylan Inc., MYL +0.17% have signed inversions of their own. Meanwhile, others like Merck & Co. and Novartis AG NOVN.VX -0.57% have struck deals to reshape their portfolios.

Pfizer, maker of drugs like the cholesterol fighter Lipitor and painkiller Celebrex, looked at Actavis as a potential alternative, the person said. In addition to potential tax savings, Actavis offered Pfizer the chance to obtain some drugs like fast-growing bowel treatment Linzess; though like Pfizer, Actavis is dealing with some aging big sellers.

A combination of the two companies would have created a behemoth in the industry with a market value of more than $250 billion.

Bloomberg earlier reported that Pfizer had approached Actavis.

In the first half of this year, pharmaceutical companies agreed to $87 billion in merger transactions, $8 billion more than in all of last year, according to industry researcher EvaluatePharma. Many companies have been using deals either to narrow their focus to markets they think they can lead, or to save on taxes and use their cash more efficiently.

>>> US options activity

* WLT Oct 3.5 calls are seeing interest with the underlying stock +7% following interest payment news and peer BTU guidance (volume: 3060, open int: 70, implied vol: ~108%, prev day implied vol: 99%)  -- we noted unusual put activity earlier this month (see 9/11 14:01 OPTNX). Co is expected to report earnings late October. * DRYS Oct 3 calls (volume: 4.1K, open int: 1.3K, implied vol: ~50%, prev day implied vol: 47%)  -- co is expected to report earnings early November. * RAX Oct 32 calls are seeing interest with continued weakness in the underlying stock (volume: 4270, open int: 1080, implied vol: ~40%, prev day implied vol: 38%)   -- co ended Formal Evaluation of M&A Transactions last week (stock has since been under considerable pressure). * AER Jan15 47.5 calls (volume: 5360, open int: 190, implied vol: ~28%, prev day implied vol: 26%)  -- one 5K transaction traded on the offer. Co is scheduled to present next week on Sept 29 at RBC conference and expected to report earnings early November.

Notable Call Activity following M&A speculation:

* GOGO calls are seeing interest with the underlying stock +2% on renewed Verizon takeover rumor. More than 6.2K total calls have traded vs 160 puts with most notable volume in the Oct 19/20 calls. GOGO is expected to report earnings early November. * VOD is seeing heavy call buying as renewed AT&T M&A speculation circulates (20K+ total calls have traded vs 1.4K puts). VOD reports earnings November 11 before the open.

Bearish Put Activity:

* DF Oct 13 puts (volume: 6730, open int: 0, implied vol: ~42%, prev day implied vol: 36%)  -- co is expected to report earnings mid-November.

Pfizer Said to Have Approached Actavis About Possible Takeover

--> -ve for AZN...

+------------------------------------------------------------------------------+

Pfizer Said to Have Approached Actavis About Possible Takeover 2014-09-23 18:12:22.519 GMT

By Jeremy R. Cooke Sept. 23 (Bloomberg) -- Pfizer has approached Actavis to express its interest in an acquisition, people with knowledge of the matter told Bloomberg’s Manuel Baigorri, David Welch and Matthew Campbell. * PFE, ACT aren’t currently in formal talks and PFE hasn’t made an offer, the people said * NOTE: Pfizer continues to explore ways to cut its tax rate and gain a new product pipeline * Although AstraZeneca rebuffed its approach, PFE still considering pursuing that deal as well as other options, the people said * PFE determined any such deal needs to be friendly, unlike the unsolicited offer made to Astra * PFE, ACT reps declined to comment * NOTE: Actavis Would Be Willing Seller if Offer Compelling, DealReporter Said (Sept. 19); Actavis Would Make Sense as M&A Target for Pfizer: Bernstein (Sept. 15) Link to full story: NSN NCD96X6TTDSS<GO>

For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>

To contact the reporter on this story: Jeremy R. Cooke in Boston at +1-617-210-4654 or jcooke8@bloomberg.net To contact the editor responsible for this story: Larry DiTore at +1-212-617-1603 or lditore@bloomberg.net

(BFW) Volume of Inversion Deals Likely to Increase, Panmure Says


Volume of Inversion Deals Likely to Increase, Panmure Says
2014-09-23 16:29:17.311 GMT


By Joshua Fineman
Sept. 23 (Bloomberg) -- Volume of tax-inversion deals
likely to increase in coming months as political rhetoric
against combos increase in U.S., UK, Panmure analyst Simon
French said in note earlier.
* Pending inversion deals likely to be “subverted, but not
destroyed”
* Remain bullish, inversion opportunites “have not
vanished,” though must adapt to more “hostile” political
environment
* NOTE: Earlier, Anti-Inversion Rules Won’t Stop Pending
Deals: Robert Willens; Inversions Still Possible Despite
Treasury Notice: Cadwalader
* NOTE: INVERSION WRAP: Earnings Stripping Guide, Tax Treaty
Action Next
* Eight Pending M&A Inversions Exposed to Treasury Tax
Limits: BI


For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
Joshua Fineman in New York at +1-212-617-8953 or
jfineman@bloomberg.net
To contact the editor responsible for this story:
Arie Shapira at +1-212-617-1488 or
ashapira3@bloomberg.net

WSJ : Clorox Shares Look Pricey, No Matter Who’s Buying (Or Isn’t)

Clorox Shares Look Pricey, No Matter Who’s Buying (Or Isn’t)

Clorox Co.CLX -1.69% jumped 7.4% on Monday, after the New York Post reported over the weekend that the consumer-products company had recently rejected a takeover approach with a 20% premium. But B Riley isn’t convinced there’s a potential buyer, and downgraded Clorox to sell, while sticking with its $77 price target.

“”The stock’s valuation is very high and fundamentals are weak,” the investment bank contends, highlighting Clorox’s operating-profit drops in three of the past five years. Shares were down 1.5% on Tuesday, at $95.75.

Before going through potential buyers, the firm wonders why anyone would be interested now in Clorox when it could have been bought for less 3 years ago. Then, Carl Icahn pushed for the sale and himself launched a takeover effort. No other bids emerged and the billionaire eventually walked away.

As for today, B Riley points out Procter & Gamble Co.PG -0.12% (PG) has gotten out of bleach and is “a net seller” of assets anyway. Meanwhile, Unilever ULVR.LN -1.04% PLC (UL) left the North American detergent market several years ago and “wants to get bigger in personal care, not household products.”

Among smaller players, Church & Dwight Co.CHD -0.36% (CHD) and Jarden Corp.JAH +0.33% (JAH) aren’t seen as likely buyers either—though not necessarily because their $8 to $9 billion market caps trail Clorox’s $13 billion. Jarden “has historically bought cheaper durable-goods companies and not the more-expensive consumables companies,” and B Riley thinks Church & Dwight “is more interested in personal care and [over-the-counter] healthcare.”

The firm also looks at potential overseas buyers of Clorox, which B Riley says would benefit from international distribution. It sees Clorox fitting strategically with German’s Henkel AGHEN3.XE -1.10% and the UK’s Reckitt Benckiser Group RB.LN -1.59% PLC, but Henkel had a 30% stake in Clorox it sold back several years ago. Reckitt, meanwhile, could run in to US antitrust concerns in household cleaners, as might be the case with closely held SC Johnson & Son Inc.

WSJ : Ryan Holmes: Why Twitter, Facebook and Apple Suddenly Want to Handle Your

RYAN HOLMES: As trends go, this one is hard to miss. In the space of a recent week, both Twitter and Apple made major announcements about payments — i.e. how we buy things online and in real life. Twitter has just rolled out a “buy” button, which appears alongside certain tweets and allows users to make purchases directly through Twitter with just a click or two. Apple, meanwhile, unveiled Apple Pay at its iPhone 6 event. The new mobile wallet app will allow users to “tap and pay” with their iPhones at more than 200,000 brick-and-mortar stores in the U.S., as well as execute online purchases.

At the same time, Facebook has been beta-testing its own “buy” button, which shows up next to posts and ads, allowing users to complete a purchase without ever leaving the network. And Google, of course, has been trying to get its tap-and-go Google Wallet app to catch on for years. (Adoption has been stymied by the fact that Apple won’t allow its hundreds of millions of iPhone users to access the app, among other reasons.)

So what’s behind this race to payments and why do social networks now want in?

On one level, in-stream purchasing on Twitter and Facebook represents the next logical step in making it easier for you and your money to part ways. The advent of credit cards freed consumers from the obligation of actually having cash on hand and heralded a new era of impulse shopping. Amazon’s famous “1-click” checkout took this a step further: Once your credit card was on file, just about anything under the sun could be bought and shipped with the press of a mouse. But you still had to go actually go to the Amazon website… and there lies the friction.

The logic behind introducing e-commerce into social networks is that you’re already there anyway, chatting with friends, browsing the latest trends, sharing photos and videos, etc. You don’t have to go to a special site to do your buying; the products come to you. And you don’t have to click away to another site to consummate the purchase — once your payment details are on file with Twitter or Facebook, purchases are a tap or two away. Then it’s back to cat GIFs and catching up with friends.

It’s also important to note that Facebook and especially Twitter are real-time media, perfect for short-term promotions and special deals tied in with fleeting trends. With time-sensitive offers literally streaming by, consumers may well be inclined to act quickly and seal the deal, forgoing the obsessive comparison shopping that characterizes lots of Internet transactions.

Selling directly on social media has another key benefit: Retailers and advertisers get instant confirmation of the impact of their social media marketing efforts. A recent Wall Street Journal report noted that while social media marketing budgets are expected to more than double in the next five years, only 15% of marketing executives can show the quantitative impact of spending. Connecting individual Tweets and Facebook posts with actual purchases has thus far proven to be a huge analytical challenge. But with the advent of buy buttons and in-stream purchasing, concrete revenue and conversion figures can be attached to social media efforts in a way that hasn’t been possible until now.

But what’s in it for the social networks themselves and — more broadly — for Apple and other makers of mobile wallet apps? For now, Facebook and Twitter are testing their buy buttons with a select group of merchants, in many cases free of charge. It’s foreseeable, however, that they’ll start charging a fee for sellers using the feature or even set up a revenue sharing system (akin to Apple’s iTunes model). The buttons — with their promise of rich data on buying patterns — may also prove useful in luring more advertisers to the networks and boosting overall revenue from ad sales.

It’s also critical to note that, to facilitate repeat transactions, both Facebook and Twitter will store users’ credit card information. Twitter, for instance, is partnering with payments processor Stripe to handle transactions. Facebook’s new Autofill feature (a kind of Facebook Connect for credit cards) allows users who enter their credit card info to check out not only on the network but with 450,000 e-commerce merchants across the web. Apple meanwhile already has an astonishing 800 million credit cards associated with iTunes accounts. The new Apple Pay app encourages users to link additional American Express, Mastercard and Visa cards to their accounts. And here’s where things really get interesting.

Right now, Apple, Twitter and Facebook are all content to act as middlemen more or less, connecting consumers with other parties who process payment — from credit card companies to online services like Stripe and PayPal. These processors, of course, skim a healthy chunk off the top of all transactions — around 2% for most credit cards; 2.9% for Stripe. In the U.S. alone, credit card interchange fees — generally borne solely by merchants and vendors — represent a $40-billion-a-year industry.

But who says Apple, Twitter and Facebook have to remain on the sidelines while all this money changes hands on their sites and services? Indeed, it’s already been revealed that Apple will get a per-transaction fee from card-issuing banks each time iPhone users pay with the Apple Pay app. This fee will come directly from the banks, rather than from merchants or consumers. (Banks seem content to part with this extra fee because of the additional business Apple Pay will bring their way.)

But why stop there? Should Apple Pay or in-stream purchasing in Twitter and Facebook truly catch on, it’s foreseeable that these companies will themselves start to act on some level as payment processors. By elbowing out credit card companies and their online equivalents, and possibly offering merchants more attractive fees and terms, Apple and these networks could theoretically have a much bigger chunk of the extraordinarily lucrative payments pot.

This may sound a bit far-fetched, especially considering that Apple Pay’s launch is predicated on partnerships with Visa, MasterCard and American Express. Without these credit card companies on board – willing to let cardholders access their cards through the app — Apple Pay would be a nonstarter. But Apple has embraced more than few strategic partners throughout its recent history only to let them loose once their purpose had been served. Think back to how restricted the Skype calling app was when the original iPhone was unveiled in 2007, in all likelihood due to Apple’s initial partnership with exclusive carrier AT&T. By contrast, the new iOS 8 operating system allows Wi-Fi calling, enabling users to make standard voice calls over a Wi-Fi network and bypass the carrier entirely. The game has changed. I predict that this same playbook is going to be used with payment partners. Expect to see an Apple finance arm in the future.

Nor does the payments arms race have to end there. Google and Microsoft may well dive further into the payments space in the years ahead. Might they perhaps acquire Square, or even Twitter, as a way to connect mobile, social and payments? The service fees charged to merchants are only one potential revenue stream here. The rich pool of data on consumers’ buying habits collected from these transactions may prove equally as valuable, with advertisers and retailers willing to pay top dollar for insight on how to better target buyers.